All lobbying filings

OGR

OGR filed a Q4 report for Amgen USA Inc. on January 17, 2026, reporting $50,000 in lobbying income.

Lobbying for Amgen USA Inc.

As filed: OGR for AMGEN USA INC.

All filings by OGR · Everything Amgen USA Inc. has reported

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 17, 2026

Income

$50,000

What the client paid this registrant for the period.

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Medicare/Medicaid

Issues related to Medicare Part D and Medicare Part B reimbursement and coverage. Issues related to drug pricing. Issues related to biosimilar regulation.

Taxation/Internal Revenue Code

Issues related to Puerto Rico.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.